Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Recruiting now · Phase 2

Conditions studied: Nasopharyngeal Carcinoma

In brief

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Key facts

Study ID

NCT06055816

Run by

Zhejiang Cancer Hospital

People needed

40

Starts

2023-09-28

Expected to finish

2028-06-30

Last updated by the study team

2023-09-28

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged ≥65 years with newly pathologically confirmed NPC
• Karnofsky performance status ≥60
• Clinical stage III-IVA (Union for International Cancer Control and American Joint Committee on Cancer staging system for NPC, 8th edition)
• Adequate organ function

You may not qualify if…

• Cancer history
• Prior radiotherapy, cytotoxic chemotherapy, immunotherapy or target therapy
• Life-expectance within 6 months

Where it is running

• Zhejiang Cancer Hospital — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.